Story perspectives

Johnson & Johnson's Caplyta Gains FDA Approval for Depression

11/6/2025

25 2

Summary

Story summary

Johnson & Johnson (the company) received U.S. Food and Drug Administration (FDA) approval to treat major depressive disorder with Caplyta.
The approval expands Caplyta beyond schizophrenia and bipolar depression.
The move follows Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies, the developer of Caplyta.
Caplyta shows 80% response and 65% remission.
Caplyta generated $240 million in sales in the third quarter and is being studied for other neurological disorders.

1 of 1

Story summary

Johnson & Johnson (the company) received U.S. Food and Drug Administration (FDA) approval to treat major depressive disorder with Caplyta.
The approval expands Caplyta beyond schizophrenia and bipolar depression.
The move follows Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies, the developer of Caplyta.
Caplyta shows 80% response and 65% remission.
Caplyta generated $240 million in sales in the third quarter and is being studied for other neurological disorders.